dihexa dihexa dihexa (developmental code name pnb-0408), also known as n-hexanoic-tyr-ile-(6) aminohexanoic amide, is an oligopeptide drug derived from angiotensin iv that binds with high affinity to hepatocyte growth factor (hgf) and potentiates its activity at its receptor, c-met. the compound has been found to potently improve cognitive function in animal models of alzheimer's disease-like mental impairment. in an assay of neurotrophic activity, dihexa was found to be seven orders of magnitude more potent than brain-derived neurotrophic factor. dihexaclinical dataother namesn-(1-oxohexyl)-l-tyrosyl-n-(6-amino-6-oxohexyl)-l-isoleucinamideidentifiers iupac name 6--3-methylpentanamido]hexanamide cas number1401708-83-5pubchem cid129010512chemspider57582587unii9wyx65a5c2chemical and physical dataformulac27h44n4o5molar mass504.672 g·mol−13d model (jsmol)interactive image smiles cccccc(=o)n(cc1ccc(o)cc1)c(=o)n((c)cc)c(=o)ncccccc(n)=o inchi inchi=1s/c27h44n4o5/c1-4-6-8-12-24(34)30-22(18-20-13-15-21(32)16-14-20)26(35)31-25(19(3)5-2)27(36)29-17-10-7-9-11-23(28)33/h13-16,19,22,25,32h,4-12,17-18h2,1-3h3,(h2,28,33)(h,29,36)(h,30,34)(h,31,35)/t19-,22-,25-/m0/s1key:xeuvnvnavkzspt-jtjyxvoqsa-n according to a patent, "short duration safety studies with dihexa have uncovered no apparent toxicity. of particular note is a lack of neoplastic induction, since c-met is recognized as an oncogene. this is unsurprising since oncogenesis requires multiple mutations including both oncogene induction and tumor suppressor attenuation." history dihexa was developed by joseph harding and his team at washington state university. later developments were done under "m3 biotechnology", a company founded to commercialise dihexa.